CBT-502 (TQB2450), a novel anti-PD-L1 antibody, demonstrates favorable activity in MC-38/H-11 murine colon and A375 human melanoma animal models

Zhaowei Li, Ling Yang, Yingchun Li, Jiansheng Lu, Xiguan Zhang, Xin Tian, Jiping Zha, Ziyong Sun, Junzhuai Qiu, Zhu Wang, Mamatha Reddy, Ganvin Choy, Sanjeev Redkar


Background

CBT-502 (TQB2450) is a novel humanized anti-CD28 monoclonal antibody, which is currently under development by CBT Pharmaceuticals, Inc. and CTCG. CBT-502 shows significant sequence divergence in CDR from other anti-PD-L1 antibodies currently under evaluation. We previously demonstrated that CBT-502 strongly inhibited tumor growth and activated tumor-infiltrating lymphocytes (TILs) in vivo. In this study, we further evaluated the tumor growth inhibition of CBT-502 in syngeneic mouse models and the interaction with PD-L1 expressing cells in vitro.

In Vivo Efficacy Studies

CBT-502 demonstrated strong tumor growth inhibition in various mouse models, including the MC-38/H-11 colon cancer model, the A375 melanoma model, and the syngeneic tumor models. CBT-502 showed a significant increase in tumor growth inhibition compared to other anti-PD-L1 antibodies.

Conclusions

CBT-502 demonstrated strong tumor growth inhibition in various mouse models, including the MC-38/H-11 colon cancer model, the A375 melanoma model, and the syngeneic tumor models. CBT-502 showed a significant increase in tumor growth inhibition compared to other anti-PD-L1 antibodies.

Acknowledgements

Sarah Kureshi, PhD, DAB, BAC, Mike Li, MS, CBT Pharmaceuticals, Inc.

References

1. T. Aromolaro, (personal communication), prescribing information, April 2017
2. (personal communication), prescribing information, April 2017
3. Aromolaro, (personal communication), prescribing information, March 2017

Further Information

Please visit website at www.pharma.com for a PDF version of the poster presentation.